High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.
To investigate whether genetic factors of innate immunity might influence susceptibility and/or progression in individuals infected with SARS, we evaluated the CD14 gene polymorphism in 198 Hong Kong blood donors and 152 Hong Kong severe acute respiratory syndrome (SARS) patients who were previously genotyped for FcgammaRIIA polymorphisms. The prevalence of the CD14-159CC polymorphism was significantly higher in the patients with severe SARS than in the those with mild SARS or controls (31% versus 15% [mild SARS] or 20% [controls]; mild SARS: P = 0.029; odds ratio, 2.74; 95% confidence interval, 1.15 to 6.57; controls, P = 0.04; odds ratio, 2.41; 95% confidence interval, 1.05 to 5.54), and both CD14-159CC and FcgammaRIIA-RR131 are risk genotypes for severe SARS-CoV infection.
Yuan
Fang F
FF
Cell Biology Laboratory, ARCBS-Endeavour, 153 Clarence Street, Sydney, NSW 2000, Australia. fyuan@arcbs.redcross.org.au
Boehm
Ingrid
I
Chan
Paul K S
PK
Marks
Katherine
K
Tang
Julian W
JW
Hui
David S C
DS
Sung
Joseph J Y
JJ
Dyer
Wayne B
WB
Geczy
Andrew F
AF
Sullivan
John S
JS
D016022:Case-Control Studies; D016001:Confidence Intervals; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D018950:Lipopolysaccharide Receptors / Q000235:genetics* / Q000276:immunology; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D015995:Prevalence; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000235:genetics* / Q000276:immunology; D012720:Severity of Illness Index; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism
D018950:Lipopolysaccharide Receptors; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4